Proschak E
Proschak E
Junior Professor in Drug Design
Verified email at
Cited by
Cited by
PocketPicker: analysis of ligand binding-sites with shape descriptors
M Weisel, E Proschak, G Schneider
Chemistry Central Journal 1, 1-17, 2007
Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds
E Proschak, H Stark, D Merk
Journal of medicinal chemistry 62 (2), 420-444, 2018
Spirocyclic scaffolds in medicinal chemistry
K Hiesinger, D Dar’in, E Proschak, M Krasavin
Journal of Medicinal Chemistry 64 (1), 150-183, 2020
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
M Hartenfeller, H Zettl, M Walter, M Rupp, F Reisen, E Proschak, ...
PLoS computational biology 8 (2), e1002380, 2012
The holistic integration of virtual screening in drug discovery
Y Tanrikulu, B Krüger, E Proschak
Drug Discovery Today 18 (7-8), 358-364, 2013
Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria
FM Klingler, TA Wichelhaus, D Frank, J Cuesta-Bernal, J El-Delik, ...
Journal of medicinal chemistry 58 (8), 3626-3630, 2015
Inhibitors of the arachidonic acid cascade: interfering with multiple pathways
K Meirer, D Steinhilber, E Proschak
Basic & clinical pharmacology & toxicology 114 (1), 83-91, 2014
Voyages to the (un) known: adaptive design of bioactive compounds
G Schneider, M Hartenfeller, M Reutlinger, Y Tanrikulu, E Proschak, ...
Trends in biotechnology 27 (1), 18-26, 2009
Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization
M Hartenfeller, E Proschak, A Schüller, G Schneider
Chemical biology & drug design 72 (1), 16-26, 2008
Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases
ÓM Bautista‐Aguilera, S Hagenow, A Palomino‐Antolin, V Farré‐Alins, ...
Angewandte Chemie International Edition 56 (41), 12765-12769, 2017
Computational tools for polypharmacology and repurposing
J Achenbach, P Tiikkainen, L Franke, E Proschak
Future medicinal chemistry 3 (8), 961-968, 2011
Lipoxin and resolvin biosynthesis is dependent on 5‐lipoxygenase activating protein
C Lehmann, J Homann, AK Ball, R Blöcher, TK Kleinschmidt, ...
The FASEB Journal 29 (12), 5029-5043, 2015
Kernel approach to molecular similarity based on iterative graph similarity
M Rupp, E Proschak, G Schneider
Journal of chemical information and modeling 47 (6), 2280-2286, 2007
Opportunities and challenges for fatty acid mimetics in drug discovery
E Proschak, P Heitel, L Kalinowsky, D Merk
Journal of medicinal chemistry 60 (13), 5235-5266, 2017
Multi-target approaches in metabolic syndrome
FF Lillich, JD Imig, E Proschak
Frontiers in pharmacology 11, 554961, 2021
2, 4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization
K Sander, T Kottke, Y Tanrikulu, E Proschak, L Weizel, EH Schneider, ...
Bioorganic & medicinal chemistry 17 (20), 7186-7196, 2009
A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis
J Schmidt, M Rotter, T Weiser, S Wittmann, L Weizel, A Kaiser, J Heering, ...
Journal of medicinal chemistry 60 (18), 7703-7724, 2017
Nonacidic farnesoid X receptor modulators
D Flesch, SY Cheung, J Schmidt, M Gabler, P Heitel, J Kramer, A Kaiser, ...
Journal of Medicinal Chemistry 60 (16), 7199-7205, 2017
PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation
S Kolodziej, ON Kuvardina, T Oellerich, J Herglotz, I Backert, N Kohrs, ...
Nature communications 5 (1), 3995, 2014
Form follows function: Shape analysis of protein cavities for receptor‐based drug design
M Weisel, E Proschak, JM Kriegl, G Schneider
Proteomics 9 (2), 451-459, 2009
The system can't perform the operation now. Try again later.
Articles 1–20